TICKERNERD
Menu
INKTINKTHealthcare · Biotechnology

INKT Stock Forecast: MiNK Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$12
−1.93% on the day

The 2 Wall Street analysts covering MiNK Therapeutics, Inc. hold a median 12-month price target of $39 — +219.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$63.5M
Ticker Nerd rank
61 / 100
Median analyst target
$39
Analysts covering
2
Revenue$0.0
Operating income−$3.2M
Net income−$3.1M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.7%
1M
+4.8%
YTD
+9.4%
1Y
−18.7%
From 52W high
−19.7%
From 52W low
+42.5%
$9
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INKT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MiNK Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Size
80
Issuance
73
Revisions
68
Volatility
68
Momentum
52
Value
37
Growth
26
Quality
21

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26INKTHigh $43Median $39Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $35Median $39High $43

The green dot is the last close — the median target sits +219.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026HC Wainwright & Co.ReiteratesBuy$35
1 Apr 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.UpgradeBuy—
15 July 2025HC Wainwright & Co.DowngradeNeutral—
14 July 2025William BlairDowngradeMarket Perform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Feb 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024BairdMaintainsOutperform—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
9 Oct 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
19 Apr 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2023Evercore ISI GroupMaintainsOutperform—
22 Mar 2023HC Wainwright & Co.ReiteratesBuy—
10 Aug 2022HC Wainwright & Co.InitiatesBuy—
24 Jan 2022B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INKT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, MiNK Therapeutics, Inc. returned −18.7% against +17.0% for the S&P 500, dividends included.

INKT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26INKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

MiNK Therapeutics, Inc. (INKT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.2×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
−4.5×

Cheaper than 96% of US stocks

EV / EBITDA
−4.6×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
87.8%

Higher than 96% of US stocks

Return on assets
−123.8%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MiNK Therapeutics, Inc. (INKT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MiNK Therapeutics, Inc. has a market value of $63.5M and an enterprise value of $54.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.8M.

  • Shares outstanding: 5.1M.

  • Trailing P/E: −4.2×; forward P/E: −4.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MiNK Therapeutics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

INKT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INKTMiNK Therapeutics, Inc.$63.5M
61
ACETAdicet Bio, Inc.$62.3M
40
HYFTMindWalk Holdings Corp.$62.6M
51
ELOXEloxx Pharmaceuticals, Inc.$62.6M
12
PLRXPliant Therapeutics, Inc.$64.1M
67
XLOXilio Therapeutics, Inc.$59.2M
74
GUTSFractyl Health, Inc.$64.5M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MiNK Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INKT news & analysis

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

GlobeNewsWire · 2 Oct 2026positive

MiNK Therapeutics announced it will present two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address tumor-cell killing in checkpoint inhibitor-resistant colorectal cancer liver metastases and the elimination of senescent tumor cells and fibroblasts.

Why it matters — The presentations highlight MiNK's research progress in challenging cancer indications, potentially expanding the applicability of its allo-iNKT cell therapy platform.

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

GlobeNewsWire · 30 Sept 2026positive

MiNK Therapeutics' clinical-stage agenT-797 iNKT platform was selected as a therapeutic cell platform for the ARPA-H-funded BoSS program, an initiative aimed at advancing living medicines from cryogenic storage toward room-temperature storage.

Why it matters — This selection validates MiNK's agenT-797 platform and could position the company at the forefront of improving the practicality and accessibility of cell therapies if the room-temperature initiative progresses.

MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

MiNK Therapeutics published the transcript of its Q2 2026 earnings call via Seeking Alpha. The document covers the company's financial results and management commentary for the quarter.

Why it matters — An INKT watcher would look to this transcript for the company's latest financial results and management's remarks on its clinical programs and outlook.

MiNK Therapeutics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

MiNK Therapeutics announced during its Q2 2026 earnings call that it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome (ARDS).

Why it matters — A MiNK Therapeutics watcher would care because advancing agenT-797 into a randomized Phase II trial marks a key clinical milestone for the company's lead pipeline candidate.

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

GlobeNewsWire · 13 Aug 2026neutral

MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797. The company also reported observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.

Why it matters — The update provides INKT watchers with the company's latest financial position and new clinical data on its lead iNKT cell therapy candidate, agenT-797.

FAQ

Frequently asked questions about INKT stock

What is the INKT stock price forecast for 2026-2027?

The 2 Wall Street analysts covering MiNK Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $35 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INKT stock a buy right now?

Of the 2 analysts covering MiNK Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiNK Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INKT?

As at 3 Oct 2026, MiNK Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will INKT stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +219.7% from the last close, and Ticker Nerd's factor model ranks MiNK Therapeutics, Inc. 61 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INKT stock forecast for 2030?

No analyst covering MiNK Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $43 over the next 12 months.

How has INKT stock performed over the past year?

MiNK Therapeutics, Inc. returned -18.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MiNK Therapeutics, Inc. do?

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.

What is the latest news on INKT?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026". MiNK Therapeutics announced it will present two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address tumor-cell killing in checkpoint inhibitor-resistant colorectal cancer liver metastases and the elimination of senescent tumor cells and fibroblasts.

Company

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions. MiNK Therapeutics works at the intersection of cell therapy and immunology, using iNKT cells that are intended to combine tumor-targeting activity with immune-regulating properties. Its current work centers on advancing product candidates through clinical development and building a manufacturing approach suited to reproducible, off-the-shelf delivery. Headquartered in New York, MiNK Therapeutics plays a specialized role in the biotechnology market by developing precision immunotherapies for serious diseases with limited treatment options.

CEO Dr. Jennifer S. Buell Ph.D. · 15 employees · United States · https://minktherapeutics.com